Drugs / IC43
IC43
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05975151 | Oct 2023 → Aug 2025 | urinary bladder cancer | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07460297 | Apr 2025 → Jan 2028 expected | — | Jianyi Li | Enrolling by invitation | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00778388 Comparator | Sep 2008 → Sep 2009 | — | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00876252 Comparator | Dec 2008 → Feb 2010 | pneumonia caused by pseudomonas aeruginosa infection | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01563263 Comparator | Mar 2012 → Aug 2015 | Pseudomonas aeruginosa infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC43 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01563263 ↗ |
| Known as | PAP | “Using two to six vials of PAP（Inactivated Pseudomonas aeruginosa injection） preparation combined with 100ml of iodophor to soak the implant and irrigate the surgical cavity.” NCT07460297 ↗ |
| Known as | Pseudomonas aeruginosa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05975151 ↗ |
| Modality | Vaccine | “IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.” NCT00778388 ↗ |
| Route | Intramuscular | “IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.” NCT00778388 ↗ |